NI201600089A - Análogos de cortistatina y síntesis y usos de los mismos - Google Patents
Análogos de cortistatina y síntesis y usos de los mismosInfo
- Publication number
- NI201600089A NI201600089A NI201600089A NI201600089A NI201600089A NI 201600089 A NI201600089 A NI 201600089A NI 201600089 A NI201600089 A NI 201600089A NI 201600089 A NI201600089 A NI 201600089A NI 201600089 A NI201600089 A NI 201600089A
- Authority
- NI
- Nicaragua
- Prior art keywords
- methods
- modulation
- activity
- same
- cdk8
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Diabetes (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporcionan en la presente compuestos de la fórmula (A), (B), (C), (D) y (E), sales farmacéuticamente aceptables, sales de aminas cuaternarias, y N-óxidos de los mismos, y composiciones farmacéuticas de los mismos. Se contemplan compuestos de la Fórmula (A), (B), (C), (D), y (E) útiles como agentes terapéuticos para el tratamiento de una amplia variedad de condiciones, ej., incluyendo, pero no limitadas a, afecciones asociadas con la angiogénesis y con CDK8 y/o actividad de la quinasa CDK19, Además, se proporcionan métodos para inhibir la actividad de las quinasas CDK19 y/o CDK8, los métodos de modulación de la vía de B-catenina, métodos de modulación de la actividad de STAT1, métodos de modulación de la vía TGFB/BMP, métodos de modulación de la actividad de HIF-1 alfa en una célula, y métodos de aumento de la expresión de BIM para inducir la apoptosis, utilizando un compuesto de la Fórmula (A), (B), (C), (D), o (E). Además, se proporcionan mutantes puntuales en CDK8 y CDK19, y métodos de uso de los mismos.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361920674P | 2013-12-24 | 2013-12-24 | |
| US201461935240P | 2014-02-03 | 2014-02-03 | |
| US201461993329P | 2014-05-15 | 2014-05-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NI201600089A true NI201600089A (es) | 2016-08-18 |
Family
ID=52350382
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NI201600089A NI201600089A (es) | 2013-12-24 | 2016-06-23 | Análogos de cortistatina y síntesis y usos de los mismos |
Country Status (30)
| Country | Link |
|---|---|
| US (3) | US9994582B2 (es) |
| EP (2) | EP3505521A1 (es) |
| JP (2) | JP6494631B2 (es) |
| KR (1) | KR20160101162A (es) |
| CN (2) | CN110183461A (es) |
| AP (1) | AP2016009324A0 (es) |
| AU (2) | AU2014369834B2 (es) |
| BR (1) | BR112016014760A2 (es) |
| CA (1) | CA2934819A1 (es) |
| CL (1) | CL2016001631A1 (es) |
| CR (1) | CR20160291A (es) |
| DO (1) | DOP2016000158A (es) |
| EA (2) | EA030907B1 (es) |
| EC (1) | ECSP16062174A (es) |
| ES (1) | ES2709480T3 (es) |
| GT (1) | GT201600135A (es) |
| IL (1) | IL246390A0 (es) |
| MD (1) | MD20160089A2 (es) |
| MX (1) | MX361652B (es) |
| MY (1) | MY180383A (es) |
| NI (1) | NI201600089A (es) |
| PE (1) | PE20161405A1 (es) |
| PH (1) | PH12016501258A1 (es) |
| RU (1) | RU2016126503A (es) |
| SA (1) | SA516371410B1 (es) |
| SG (2) | SG10201808151RA (es) |
| SV (1) | SV2016005234A (es) |
| TN (1) | TN2016000240A1 (es) |
| WO (1) | WO2015100420A1 (es) |
| ZA (1) | ZA201603894B (es) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3505521A1 (en) | 2013-12-24 | 2019-07-03 | President and Fellows of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| EP3102576B8 (en) | 2014-02-03 | 2019-06-19 | Vitae Pharmaceuticals, LLC | Dihydropyrrolopyridine inhibitors of ror-gamma |
| US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
| EP3294298A4 (en) * | 2015-05-08 | 2018-10-17 | President and Fellows of Harvard College | Cortistatin analogues, syntheses, and uses thereof |
| JP2018516884A (ja) * | 2015-05-08 | 2018-06-28 | プレジデント アンド フェローズ オブ ハーバード カレッジ | コルチスタチン誘導体による治療に対する患者の標的化選択 |
| EP3316889A4 (en) | 2015-07-01 | 2018-11-14 | President and Fellows of Harvard College | Cortistatin analogues and syntheses and uses thereof |
| US10301261B2 (en) | 2015-08-05 | 2019-05-28 | Vitae Pharmaceuticals, Llc | Substituted indoles as modulators of ROR-gamma |
| MA53943A (fr) | 2015-11-20 | 2021-08-25 | Vitae Pharmaceuticals Llc | Modulateurs de ror-gamma |
| EP3394038A4 (en) * | 2015-12-23 | 2019-08-21 | President and Fellows of Harvard College | TARGETED PATIENT SELECTION FOR TREATMENT WITH SPECIFIC CORTISTANTIDE DERIVATIVES |
| CA3009324A1 (en) * | 2015-12-23 | 2017-06-29 | President And Fellows Of Harvard College | Cortistatin analogs and uses thereof |
| TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ＲＯＲ－γ調節劑 |
| KR20180110134A (ko) * | 2016-02-19 | 2018-10-08 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 코르티스타틴 유사체 |
| US11285144B2 (en) | 2016-08-03 | 2022-03-29 | The Broad Institute, Inc. | Use of CDK8 inhibitors to treat diseases of inflammation and autoimmunity |
| US11578067B2 (en) | 2017-01-30 | 2023-02-14 | Kyoto University | Compound, and method for producing regulatory T cells |
| CN107028956A (zh) * | 2017-03-06 | 2017-08-11 | 刘杰 | 一种治疗经期抑郁症的药物组合物 |
| WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
| AU2018307919B2 (en) | 2017-07-24 | 2022-12-01 | Vitae Pharmaceuticals, Llc | Inhibitors of RORϒ |
| EP3691642B1 (en) | 2017-10-02 | 2024-03-06 | Boehringer Ingelheim International GmbH | [1,6]naphthyridine compounds and derivatives as cdk8/cdk19 inhibitors |
| CA3128377A1 (en) * | 2019-02-01 | 2020-08-06 | University Of South Carolina | Bicyclic pyridine compositions and methods of using the same for cancer therapy |
| AR127141A1 (es) | 2021-09-27 | 2023-12-20 | Univ Kyoto | Método para producir células t |
| CN118591619A (zh) | 2021-11-24 | 2024-09-03 | 雷格细胞股份有限公司 | 人诱导性调节性t细胞及其制作方法 |
| TW202334397A (zh) | 2021-11-24 | 2023-09-01 | 日商雷格細胞股份有限公司 | 用於治療或預防t細胞相關疾病之醫藥組合物 |
Family Cites Families (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2886589A (en) | 1957-08-05 | 1959-05-12 | Merck & Co Inc | 8-methyl-5-oxyphenyl hexahydroindan compounds |
| US4270537A (en) | 1979-11-19 | 1981-06-02 | Romaine Richard A | Automatic hypodermic syringe |
| US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
| US4863457A (en) | 1986-11-24 | 1989-09-05 | Lee David A | Drug delivery device |
| CA1283827C (en) | 1986-12-18 | 1991-05-07 | Giorgio Cirelli | Appliance for injection of liquid formulations |
| GB8704027D0 (en) | 1987-02-20 | 1987-03-25 | Owen Mumford Ltd | Syringe needle combination |
| US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
| US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
| US4940460A (en) | 1987-06-19 | 1990-07-10 | Bioject, Inc. | Patient-fillable and non-invasive hypodermic injection device assembly |
| US4853224A (en) | 1987-12-22 | 1989-08-01 | Visionex | Biodegradable ocular implants |
| US4997652A (en) | 1987-12-22 | 1991-03-05 | Visionex | Biodegradable ocular implants |
| US5339163A (en) | 1988-03-16 | 1994-08-16 | Canon Kabushiki Kaisha | Automatic exposure control device using plural image plane detection areas |
| FR2638359A1 (fr) | 1988-11-03 | 1990-05-04 | Tino Dalto | Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau |
| US5098443A (en) | 1989-03-23 | 1992-03-24 | University Of Miami | Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents |
| US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
| US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
| US5185152A (en) | 1990-01-10 | 1993-02-09 | Peyman Gholam A | Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye |
| US5190521A (en) | 1990-08-22 | 1993-03-02 | Tecnol Medical Products, Inc. | Apparatus and method for raising a skin wheal and anesthetizing skin |
| US5410016A (en) | 1990-10-15 | 1995-04-25 | Board Of Regents, The University Of Texas System | Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers |
| US5527288A (en) | 1990-12-13 | 1996-06-18 | Elan Medical Technologies Limited | Intradermal drug delivery device and method for intradermal delivery of drugs |
| US5378475A (en) | 1991-02-21 | 1995-01-03 | University Of Kentucky Research Foundation | Sustained release drug delivery devices |
| GB9118204D0 (en) | 1991-08-23 | 1991-10-09 | Weston Terence E | Needle-less injector |
| SE9102652D0 (sv) | 1991-09-13 | 1991-09-13 | Kabi Pharmacia Ab | Injection needle arrangement |
| US5328483A (en) | 1992-02-27 | 1994-07-12 | Jacoby Richard M | Intradermal injection device with medication and needle guard |
| IL105050A0 (en) | 1992-03-27 | 1993-07-08 | Lilly Co Eli | Steroid derivatives |
| US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
| US5569189A (en) | 1992-09-28 | 1996-10-29 | Equidyne Systems, Inc. | hypodermic jet injector |
| US5334144A (en) | 1992-10-30 | 1994-08-02 | Becton, Dickinson And Company | Single use disposable needleless injector |
| US5443505A (en) | 1993-11-15 | 1995-08-22 | Oculex Pharmaceuticals, Inc. | Biocompatible ocular implants |
| WO1995024176A1 (en) | 1994-03-07 | 1995-09-14 | Bioject, Inc. | Ampule filling device |
| US5466220A (en) | 1994-03-08 | 1995-11-14 | Bioject, Inc. | Drug vial mixing and transfer device |
| SE9401108D0 (sv) | 1994-03-31 | 1994-03-31 | Leiras Oy | Ophthalmic composition I |
| US5725493A (en) | 1994-12-12 | 1998-03-10 | Avery; Robert Logan | Intravitreal medicine delivery |
| US5599302A (en) | 1995-01-09 | 1997-02-04 | Medi-Ject Corporation | Medical injection system and method, gas spring thereof and launching device using gas spring |
| US5730723A (en) | 1995-10-10 | 1998-03-24 | Visionary Medical Products Corporation, Inc. | Gas pressured needle-less injection device and method |
| US5847172A (en) | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
| US5554187A (en) | 1995-08-18 | 1996-09-10 | Rizzo, Iii; Joseph | Medication dispensing intra-ocular lens system |
| US5893397A (en) | 1996-01-12 | 1999-04-13 | Bioject Inc. | Medication vial/syringe liquid-transfer apparatus |
| GB9607549D0 (en) | 1996-04-11 | 1996-06-12 | Weston Medical Ltd | Spring-powered dispensing device |
| US6074872A (en) | 1996-05-15 | 2000-06-13 | The Scripps Research Institute | Cortistatin: nucleic acids that encode these neuropeptides |
| ZA978537B (en) | 1996-09-23 | 1998-05-12 | Focal Inc | Polymerizable biodegradable polymers including carbonate or dioxanone linkages. |
| AU5902398A (en) | 1996-12-31 | 1998-07-31 | Human Genome Sciences, Inc. | Cortistatin polypeptides |
| US5993412A (en) | 1997-05-19 | 1999-11-30 | Bioject, Inc. | Injection apparatus |
| IT1298087B1 (it) | 1998-01-08 | 1999-12-20 | Fiderm S R L | Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni |
| US7098196B1 (en) | 1999-10-13 | 2006-08-29 | Johns Hopkins University School Of Medicine | Regulators of the hedgehog pathway, compositions and uses related thereto |
| US6632457B1 (en) | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
| US20030060425A1 (en) | 1998-11-24 | 2003-03-27 | Ahlem Clarence N. | Immune modulation method using steroid compounds |
| US6667299B1 (en) | 2000-03-16 | 2003-12-23 | Hollis-Eden Pharmaceuticals, Inc. | Pharmaceutical compositions and treatment methods |
| US6291516B1 (en) | 1999-01-13 | 2001-09-18 | Curis, Inc. | Regulators of the hedgehog pathway, compositions and uses related thereto |
| NZ515810A (en) | 1999-04-30 | 2004-05-28 | Arch Dev Corp | Steroid derivatives |
| EP2322182A1 (en) | 1999-09-30 | 2011-05-18 | Harbor BioSciences, Inc. | Androstenol derivatives as androgen receptor modulator |
| EP1223941B1 (en) | 1999-10-25 | 2008-11-05 | Hollis-Eden Pharmaceuticals Inc. | Therapeutic treatments for blood cell deficiencies using sreroids |
| CN1827621A (zh) * | 2000-03-31 | 2006-09-06 | 萨诺化学药物股份公司 | 雪花胺的新衍生物和类似物 |
| EP1392262A1 (en) | 2001-05-24 | 2004-03-03 | Alexza Molecular Delivery Corporation | Delivery of drug esters through an inhalation route |
| ITMI20011445A1 (it) | 2001-07-06 | 2003-01-06 | Europ Geie | Analoghi della cortistantina capaci di legarsi selettivamente ai recettori dei secretagoghi dell'ormone della crescita |
| AU2003208913A1 (en) | 2002-01-30 | 2003-09-02 | Entremed, Inc. | Non-steroidal analogs of 2-methoxyestradiol |
| AU2003292939A1 (en) | 2002-12-24 | 2004-07-22 | The University Of British Columbia | Angiogenic compounds and uses thereof |
| EP1608671B1 (en) | 2003-03-24 | 2010-01-06 | Sterix Limited | Oestrogen derivatives as inhibitors of steroid sulphatase |
| CA2527074A1 (en) | 2003-05-28 | 2005-04-07 | Entremed, Inc. | Antiangiogenic agents |
| CA2532802C (en) * | 2003-07-24 | 2013-11-19 | Merck & Co., Inc. | Antibiotic compound isolated from streptomyces sp |
| US20070004689A1 (en) | 2004-03-12 | 2007-01-04 | Agoston Gregory E | Antiangiogenic agents |
| GB0421106D0 (en) | 2004-09-22 | 2004-10-27 | Sterix Ltd | Compound |
| SI2206719T1 (sl) | 2005-03-02 | 2015-03-31 | University Of Maryland, Baltimore | Farmacevtski sestavek obsegajoäś 3-beta-hidroksi-17-(1-h-benzimidazol-1-il)androsta-5,16-dien |
| EP1971618A2 (en) | 2006-01-09 | 2008-09-24 | Btg International Limited | Modulators of hypoxia inducible factor-1 and related uses |
| WO2007082980A1 (es) | 2006-01-23 | 2007-07-26 | Consejo Superior De Investigaciones Científicas | Composiciones y procedimientos para tratar trastornos inflamatorios e inmunitarios con cortistatina |
| WO2007103162A2 (en) | 2006-03-01 | 2007-09-13 | Samaritan Pharmaceuticals, Inc. | Structure based drug design of steroidogenesis inhibitors |
| CA2650932C (en) * | 2006-05-09 | 2013-01-22 | Merck & Co., Inc. | Substituted spirocyclic cgrp receptor antagonists |
| EP1870405A1 (en) * | 2006-06-22 | 2007-12-26 | Bioprojet | Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands |
| WO2008064425A1 (en) | 2006-11-30 | 2008-06-05 | Solbec Pharmaceuticals Limited | Glycoalkaloid and chemotherapeutic agent combinations and various uses thereof |
| US8283345B2 (en) | 2006-12-22 | 2012-10-09 | Industrial Research Limited | Azetidine analogues of nucleosidase and phosphorylase inhibitors |
| MX2009009429A (es) | 2007-03-07 | 2010-07-05 | Infinity Discovery Inc | Analogos de ciclopamina lactama y metodos de uso de los mismos. |
| US8604004B2 (en) * | 2007-10-04 | 2013-12-10 | President And Fellows Of Harvard College | Moenomycin analogs, methods of synthesis, and uses thereof |
| CA2723689C (en) * | 2008-05-05 | 2016-07-05 | Ryan A. Shenvi | Synthesis of (+) cortistatin a and related compounds |
| US20110190323A1 (en) | 2008-08-28 | 2011-08-04 | President And Fellows Of Harvard College | Cortistatin analogues and syntheses thereof |
| WO2010123545A2 (en) | 2009-04-22 | 2010-10-28 | President And Fellows Of Harvard College | Angiogenesis inhibitors |
| US8598344B2 (en) | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
| CA2799904A1 (en) | 2010-05-20 | 2011-11-24 | F. Hoffmann-La Roche Ag | Pyrrolo [2, 3 - b] pyrazine - 7 - carboxamide derivatives and their use as jak and syk inhibitors |
| WO2012036287A1 (ja) | 2010-09-17 | 2012-03-22 | 国立大学法人大阪大学 | 新規コルチスタチンａ類似体およびその用途 |
| EP2663574A4 (en) | 2011-01-10 | 2014-12-17 | Scripps Research Inst | RETRO VIRUS REPLICATION INHIBITORS |
| EA028595B1 (ru) | 2012-02-02 | 2017-12-29 | Сенекс Биотекнолоджи Инк. | Селективные ингибиторы cdk8/cdk19 и их применение в качестве противометастатических и химиопрофилактических агентов для лечения рака |
| WO2013122609A1 (en) | 2012-02-17 | 2013-08-22 | Genentech, Inc. | Methods of using cdk8 antagonists |
| WO2014123900A1 (en) | 2013-02-05 | 2014-08-14 | Sirenas Marine Discovery | Anti-cancer and anti-hiv compounds |
| US20160000787A1 (en) | 2013-02-26 | 2016-01-07 | Senex Biotechnology, Inc. | Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer |
| EP3007686A4 (en) | 2013-06-10 | 2017-03-15 | Yeda Research and Development Co., Ltd. | Compositions and methods for treating a hematological malignancy associated with an altered runx1 activity or expression |
| PL3046933T3 (pl) | 2013-09-18 | 2019-08-30 | Bcn Peptides, S.A. | Analogi kortystatyny do leczenia chorób zapalnych i/lub immunologicznych |
| EP3505521A1 (en) | 2013-12-24 | 2019-07-03 | President and Fellows of Harvard College | Cortistatin analogues and syntheses and uses thereof |
-
2014
- 2014-12-24 EP EP18205981.6A patent/EP3505521A1/en not_active Withdrawn
- 2014-12-24 SG SG10201808151RA patent/SG10201808151RA/en unknown
- 2014-12-24 TN TN2016000240A patent/TN2016000240A1/en unknown
- 2014-12-24 CR CR20160291A patent/CR20160291A/es unknown
- 2014-12-24 SG SG11201605178WA patent/SG11201605178WA/en unknown
- 2014-12-24 AU AU2014369834A patent/AU2014369834B2/en not_active Ceased
- 2014-12-24 EA EA201691167A patent/EA030907B1/ru not_active IP Right Cessation
- 2014-12-24 MY MYPI2016001176A patent/MY180383A/en unknown
- 2014-12-24 EA EA201891279A patent/EA201891279A1/ru unknown
- 2014-12-24 MD MDA20160089A patent/MD20160089A2/ro not_active Application Discontinuation
- 2014-12-24 JP JP2016542733A patent/JP6494631B2/ja not_active Expired - Fee Related
- 2014-12-24 RU RU2016126503A patent/RU2016126503A/ru not_active Application Discontinuation
- 2014-12-24 BR BR112016014760A patent/BR112016014760A2/pt not_active Application Discontinuation
- 2014-12-24 WO PCT/US2014/072365 patent/WO2015100420A1/en active Application Filing
- 2014-12-24 PE PE2016000946A patent/PE20161405A1/es unknown
- 2014-12-24 KR KR1020167019783A patent/KR20160101162A/ko not_active Application Discontinuation
- 2014-12-24 CA CA2934819A patent/CA2934819A1/en not_active Abandoned
- 2014-12-24 CN CN201910351186.8A patent/CN110183461A/zh active Pending
- 2014-12-24 ES ES14827687T patent/ES2709480T3/es active Active
- 2014-12-24 AP AP2016009324A patent/AP2016009324A0/en unknown
- 2014-12-24 EP EP14827687.6A patent/EP3087080B1/en active Active
- 2014-12-24 CN CN201480076267.7A patent/CN106103452B/zh not_active Expired - Fee Related
- 2014-12-24 MX MX2016008436A patent/MX361652B/es active IP Right Grant
-
2016
- 2016-06-08 ZA ZA2016/03894A patent/ZA201603894B/en unknown
- 2016-06-22 IL IL246390A patent/IL246390A0/en unknown
- 2016-06-23 CL CL2016001631A patent/CL2016001631A1/es unknown
- 2016-06-23 NI NI201600089A patent/NI201600089A/es unknown
- 2016-06-24 SV SV2016005234A patent/SV2016005234A/es unknown
- 2016-06-24 US US15/192,629 patent/US9994582B2/en active Active
- 2016-06-24 DO DO2016000158A patent/DOP2016000158A/es unknown
- 2016-06-24 GT GT201600135A patent/GT201600135A/es unknown
- 2016-06-24 SA SA516371410A patent/SA516371410B1/ar unknown
- 2016-06-24 PH PH12016501258A patent/PH12016501258A1/en unknown
- 2016-07-20 EC ECIEPI201662174A patent/ECSP16062174A/es unknown
-
2018
- 2018-05-16 US US15/981,575 patent/US10273241B2/en not_active Expired - Fee Related
-
2019
- 2019-03-04 JP JP2019038398A patent/JP2019108367A/ja not_active Withdrawn
- 2019-03-05 US US16/293,410 patent/US10508121B2/en not_active Expired - Fee Related
- 2019-03-19 AU AU2019201888A patent/AU2019201888A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201600089A (es) | Análogos de cortistatina y síntesis y usos de los mismos | |
| DOP2015000241A (es) | Compuestos de biaril-amida como inhibidores de cinasa | |
| GT201400196A (es) | Compuestos de heterociclilo | |
| GT201400301A (es) | 7h-pirrolo [2,3-d] pirimidinas-4- ( aminho-substituidas) novedosas como inhibidores de lrrk2 | |
| CL2017000469A1 (es) | Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1 | |
| CR20150371A (es) | Inhibidores de prmt5 y sus usos | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| UY33536A (es) | INHIBIDORES BICÍCLICOS DE ACETIL-CoA-CARBOXILASA Y USOS DE LOS MISMOS | |
| UY35663A (es) | Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos | |
| ECSP15025947A (es) | Derivados de cloro-pirazin carboxamida con actividad bloqueadora sobre los canales de sodio epiteliales | |
| UY36265A (es) | “derivados de pirrolo[2,3-d]pirimidina”. | |
| CO2019007888A2 (es) | Inhibidores selectivos de jak1 | |
| DOP2014000036A (es) | Compuestos de piridazinona y su uso como inhibidores daao | |
| DOP2017000209A (es) | Derivados de heteroarilo bicíclico fusionados con actividad como inhibidores de phd | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| ECSP18056196A (es) | Derivados de indano | |
| ECSP099644A (es) | Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico | |
| CU20140140A7 (es) | 7H-PIRROLO[2,3-d]PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2 | |
| UY35672A (es) | Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos |